Sector: MedicalViroPharma Incorporated (NASDAQ: VPHM)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 136 |
Technical : | 212 |
Performance : | 244 |
Overall: | 235 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 238 |
Technical : | 245 |
Performance : | 253 |
Overall: | 288 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 196 |
Technical : | 122 |
Performance : | 166 |
Overall: | 189 |
Number of Stocks: | 306 |
Headlines
- Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
Nov 16, 2009 11:01 AM | VPHM
- MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)
Nov 09, 2009 02:00 PM | VPHM
- Cipher appoints Dr. William Claypool to Board of Directors
Nov 03, 2009 03:50 PM | VPHM
- ViroPharma to Present at Three November Healthcare Conferences
Oct 29, 2009 04:13 PM | VPHM
- ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Oct 28, 2009 07:31 AM | VPHM
- Hereditary Angioedema (HAE) National Surveillance Project
Oct 22, 2009 03:00 PM | VPHM
- ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009
Oct 15, 2009 04:00 PM | VPHM
- Viropharma (NASDAQ: VPHM): Upgraded To Outperform At Oppenheimer
Sep 28, 2009 09:33 AM | VPHM
- ViroPharma to Present at Four Additional Healthcare Conferences
Sep 15, 2009 08:31 AM | BAC, UBS, VPHM
- New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
Sep 10, 2009 06:00 PM | VPHM
- The Fortune Financial Global Market Perspective Review on Schnitzer Steel Industries Inc., ViroPharma Inc., T. Rowe Price Group Inc., Cirrus Logic Inc., Veeco Instruments Inc. and Teton Energy Corp.
Nov 20, 2009 07:54 AM | CRUS, SCHN, TEC, TROW, VECO, VPHM
- BenchmarkJournal.Com Free Analyst Review for OCNF, TSFG, PBCT, VPHM, WFMI and VALE
Aug 19, 2009 10:18 AM | OCNF, PBCT, TSFG, VALE, VPHM, WFMI
- ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
Aug 06, 2009 11:01 AM | VPHM
- ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Aug 04, 2009 06:38 PM | VPHM
- StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
Aug 04, 2009 06:51 AM | AZN, CBST, GSK, SLXP, VPHM
- ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Jul 29, 2009 07:55 AM | VPHM
- ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
Jul 14, 2009 03:58 PM | VPHM
- ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Jun 08, 2009 09:05 AM | VPHM
- ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Jun 04, 2009 07:31 AM | VPHM
- ViroPharma to Present at Two June Healthcare Conferences
Jun 02, 2009 03:05 PM | VPHM
- Form 4 Broom Colin MD For: Jun 11 (10K)
Jun 15, 2009 07:31 PM
- Form 4 DOYLE THOMAS F For: Jun 11 (10K)
Jun 15, 2009 07:31 PM
- Form 4 SOLAND DANIEL B For: Jun 11 (10K)
Jun 15, 2009 07:30 PM
- Form 4 Pietrusko Robert For: Jun 11 (10K)
Jun 15, 2009 07:29 PM
- Form 4 Rowland Charles A Jr For: Jun 11 (10K)
Jun 15, 2009 07:29 PM
- Form 4 MILANO VINCENT For: Jun 11 (10K)
Jun 15, 2009 07:29 PM
- Form 4 Morris Richard Steven For: Jun 11 (10K)
Jun 15, 2009 07:28 PM
- Form 4 Wolf John Peter III For: Jun 11 (10K)
Jun 15, 2009 07:28 PM
- Form 4 VIROPHARMA INC For: Jun 05 Filed by: BALDINO FRANK JR (10K)
Jun 08, 2009 03:55 PM
- Form 3 VIROPHARMA INC For: Jun 05 Filed by: BALDINO FRANK JR (10K)
Jun 08, 2009 03:55 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
VPHM
|
Compare to S&P
|
| YTD |
-40.86 %
|
-51.06 %
|
| 4 Weeks |
-17.65 %
|
-18.54 %
|
| 12 Weeks |
-5.17 %
|
-10.60 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 70.00 %
|
|
EPS Growth in Last Year: 3.03 %
|
|
Sales Growth in Last Quarter: -1.61 %
|
|
Sales Growth in Last Quarter: 22.21 %
|
|
